(Total Views: 447)
Posted On: 02/11/2025 3:43:41 PM
Post# of 155803
Considering the already high level and competence of HIV-research, taking into account A I and the ressources - not only money - GSK (or any other BP for that matter) should be in a position to develop a product against HIV within 5-6 years.
They could develop the CCR5-route (Maraviroc comes to mind) further, pursue
the mRNA-technology OR come up with something completely new, something
that is somewhere on the horizon, but develops at 'warp speed'.
Yes, it could be Leronlimab, but then I think 2030 is to far out, with LL it will
be faster.
They could develop the CCR5-route (Maraviroc comes to mind) further, pursue
the mRNA-technology OR come up with something completely new, something
that is somewhere on the horizon, but develops at 'warp speed'.
Yes, it could be Leronlimab, but then I think 2030 is to far out, with LL it will
be faster.
(2)
(0)
